Table 1.
Demographic and clinical variables in PD participants.
| Variable | PDA− (N = 33) |
PDA+ (N = 17) |
p values |
|---|---|---|---|
| Demographic | |||
| Age (years) | 68.3 (8.9) | 64.9 (8.1) | p = 0.20 |
| Gender (% male) | 19/14 (57.6%) | 9/8 (52.9%) | p = 0.75 |
| Clinical | |||
| Disease duration (years) | 6.6 (4.2) | 6.6 (5.6) | p = 0.66 |
| UPDRS-III | 31.9 (13.0) | 31.2 (15.3) | p = 0.65 |
| LPD/RPD ratio (% LPD) | 15/17 (45.5%) | 6/11 (35.3%) | p = 0.38 |
| H&Y stage, median (range) | 2.0 (1–4) | 2.0 (1–5) | p = 0.43 |
| LEDD, mg/day | 674.0 (550.5) | 710.2 (478.7) | p = 0.80 |
| HADS-A | 2.03 (1.6) | 10.5 (1.9) | ∗ p < 0.001 |
| HADS-D | 3.2 (1.7) | 4.1 (1.6) | p = 0.06 |
| HADS-total | 5.2 (2.7) | 14.7 (2.9) | ∗ p < 0.001 |
Note: values reflect mean (SD). LEDD: levodopa equivalent daily dose. ∗ indicates significant group differences.